CYCC — Cyclacel Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $95.76m
- $92.62m
- $0.04m
Annual cashflow statement for Cyclacel Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.45 | -18.9 | -21.2 | -22.6 | -11.2 |
| Depreciation | |||||
| Non-Cash Items | 0.337 | 1.33 | 1.55 | 1.4 | 0.555 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.154 | -1.02 | -1.21 | 5.01 | 2.66 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Cash from Operating Activities | -7.93 | -18.5 | -20.8 | -16.1 | -7.99 |
| Capital Expenditures | -0.096 | -0.027 | -0.007 | -0.006 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | — | — | — |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.096 | -0.027 | -0.007 | -0.006 | — |
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 29.5 | 21.7 | 3 | 0.848 | 7.82 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 21.5 | 3.15 | -18.2 | -15 | -0.241 |